Allurion Technologies Hits 52-Week Low at $1.30 Amid Financial Struggles

Allurion Technologies, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.30 on November 13, 2025. This significant decline marks a staggering 95.53% drop in the company's stock price over the past year, contrasting sharply with the S&P 500's performance of 14.49% during the same period.
The company's market capitalization stands at approximately USD 17 million, reflecting its microcap status. Allurion Technologies has been grappling with financial difficulties, evidenced by its negative book value and a weak ability to service debt, highlighted by a poor EBIT to interest ratio of -13.96. The company has reported losses and currently has a negative net worth, raising concerns about its long-term viability.

In its latest financial results, Allurion reported net sales of just USD 3.38 million, the lowest in recent quarters, alongside an 11.18% year-over-year increase in raw material costs. With a return on equity of 68.55%, the company faces significant challenges ahead, as it continues to underperform against the S&P 500 benchmark over the last three years.